Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

doi:10.1007/s11523-026-01203-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Targeted oncology - 1 Mar 2026

Ko How-Wen, Liao Ying-Ting, Liang Sheng-Kai, Huang Yen-Hsiang, Lin Yu-Ching, Liu Ping-Chi, Wang Chin-Chou, Tsai Jeng-Shiuan, Chen Yuh-Min, Shih Jin-Yuan, Yang Tsung-Ying, Yang Cheng-Ta

Abstract excerpt

BACKGROUND: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)-sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies-remains debated. OBJECTIVE: The Giotrif In Advanced NSCLC Taiwan (GIANT) study evaluated the real-world outcomes of sequential afatinib-based strategies. PATIENTS AND METHODS: This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to Indoles

Share to Pyrimidines

Share to Taiwan

Source

Open in PubMed Open full text

Identifiers

PMID: 41862776
DOI: 10.1007/s11523-026-01203-6
PMCID: PMC13031183

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.